Senseonics Stock Price, News & Analysis

Senseonics Holdings, a medical tech company specializing in long-term, implantable continuous glucose monitoring (CGM) systems, has released its business updates and financial outlook for 2024. The first half of 2024 saw a 21% increase in net revenue to $10 million and over a 200% rise in new patient starts in the U.S. compared to the same period in 2023. The FDA review of the new 365-day Eversense system is on track for a Q4 2024 launch. Collaborations with Mercy Health are progressing with provider training and patient identification underway.

For the full year 2024, Senseonics expects global net revenue between $22 million and $24 million, with significant growth in U.S. patient starts and a 50% increase in the global installed base. However, inventory dynamics may affect Q3 sales, with an anticipated acceleration in Q4. Cash utilization is projected to remain stable at around $70 million.

Senseonics Holdings, a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for diabetes patients, has announced a business update and analyst event. This will take place during the American Diabetes Association’s 84th Scientific Sessions in Orlando, FL. The event is scheduled for Sunday, June 23, 2024, with breakfast and refreshments starting at 9:15 am ET, followed by a management presentation at 10:00 am ET. Attendees can access the presentation via live and recorded webcast on the company's website. In-person attendance requires advanced registration by June 21, 2024, through emailing Hannah Jeffrey at hannah@gilmartinir.com.

Senseonics Holdings, a medical technology firm specializing in long-term, implantable continuous glucose monitoring (CGM) systems, announces its participation in the Sidoti Small Cap Conference. The event will take place virtually on June 12, 2024, at 1:45 pm ET. Management will hold one-on-one meetings and present key insights. The live and recorded webcast of the presentation will be available on the company's Investor Relations section at www.senseonics.com.

Senseonics Holdings, a medical technology firm specializing in long-term, implantable continuous glucose monitoring (CGM) systems, reported its Q1 2024 financial results.

The company achieved $5.1 million in revenue, a 22% increase compared to Q1 2023. However, gross profit declined to $0.3 million due to higher fixed manufacturing costs.

Notable achievements include the integration of Eversense CGM with Mercy health system, the FDA iCGM designation for Eversense, and the filing for the next-generation 365-day system.

Despite these advancements, the firm posted a net loss of $18.9 million, or $0.03 per share, significantly down from a $1.3 million net income in Q1 2023. First half 2024 revenue is projected at $10 million, a 16% growth year-over-year.

Senseonics (NYSE American: SENS) has announced a partnership with Mercy, a prominent health care system, to enhance diabetes population health management. This collaboration will utilize Senseonics' Eversense implantable continuous glucose monitor (CGM) technology and the new Eversense Remote Patient Monitoring (RPM) solution across Mercy's extensive network. Mercy, serving over 3 million patients annually, plans to implement the program in phases starting July, initially targeting 30,000 patients. This initiative aims to improve patient care, reduce hospitalizations, and provide personalized diabetes management, reaching full implementation by 2025.

Senseonics Holdings, Inc. (NYSE American: SENS) partners with Rimidi to develop the Eversense CGM+RPM solution, integrating glucose data into Rimidi's clinical management platform for diabetes management. The program aims to optimize care, improve patient outcomes, and reduce healthcare costs. The collaboration will offer a comprehensive diabetes solution, combining long-term implantable CGM technology with analytics and personalized health services.

Senseonics Holdings, Inc. (NYSE American: SENS) will be participating in two upcoming conferences: the RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York, NY. Management will engage in one-on-one meetings at both events, with the RBC conference scheduled for May 15, 2024, and the H.C. Wainwright conference on May 20, 2024. A live and recorded webcast of the presentation will be available on the 'Investor Relations' section of the company's website.

Senseonics Holdings, Inc. (NYSE American: SENS) is set to release its first quarter 2024 financial results on May 13, 2024, after the market closes. The company specializes in the development of long-term, implantable continuous glucose monitoring systems for individuals with diabetes. A conference call to discuss the performance is scheduled for 4:30 p.m. (Eastern Time) on the same day.

The Eversense® CGM System by Senseonics Holdings, Inc. has received an integrated CGM (iCGM) designation by the US FDA, allowing integration with insulin pumps for an automated insulin delivery system. Eversense is the first fully implantable device in its category with iCGM status, offering new interoperable CGM options. The partnership with Ascensia Diabetes Care aims to provide diabetes patients with advanced technology meeting high standards for accuracy, alert detection, and wear time.